Health

Dong-A Socio Holdings has absorbed its core operating subsidiary Dong-A Pharmaceutical, bringing Bacchus and other consumer healthcare businesses back under the holding company 13 years after the group separated its holding and operating entities.

Sillajen is seeking to demonstrate a new phase of growth through its BAL0891 oncology candidate, SJ-600 oncolytic virus platform and stable pharmaceutical business.

Major South Korean biotech companies are heading to BioJapan 2026 in Yokohama to pursue CDMO contracts, drug licensing deals and joint development opportunities across Japan and the broader Asia-Pacific market.

Wontech's laser medical device Velastar receives PMDA certification, enabling marketing and sales in Japan.

Celltrion expands the U.S. approval of its biosimilar Actemra, Aptozma, to include pediatric COVID-19 patients.

HLB announced that its U.S. subsidiary Elevar Therapeutics has begun the review process for the drug Liraglutide with EMA.

HLB's liver cancer drug manufacturing facility passed FDA inspection with Voluntary Action Indicated, speeding up NDA resubmission plans.

HK Inno.N's obesity treatment Ecnoglutide shows up to 12.6% BMI and 12.1% weight reduction in clinical trial for obese adolescents.

JW Pharmaceutical announced phase 3 results for the diabetes drug Anagliptin and the combination drug Empagard at EASD 2026.

Samjin Pharm has been selected for South Korea’s 2026 World Class Plus Project, securing government support for the development of new drugs, antibody-drug conjugates and other core technologies.

Yuhan Corp. will showcase its R&D and CDMO capabilities at CPHI Worldwide 2026 in Milan as it seeks to expand global partnerships and orders.

Sky Labs is launching a clinical study in the U.K. to validate the 24-hour ambulatory blood pressure monitoring performance of its cuffless CART blood pressure monitor, with the goal of securing British and Irish Hypertension Society validation and laying the groundwork for entry into the U.K. public health reimbursement system.

Celltrion has launched Omlyclo, the first omalizumab biosimilar in the U.S., for chronic spontaneous urticaria and allergic asthma, with preferred formulary placement from major pharmacy benefit manager Optum.

Appclon’s AC101 cancer drug candidate, licensed to China’s Henlius, is expanding into colorectal cancer and breast cancer that has progressed after antibody-drug conjugate treatment, bringing its total clinical programs to nine.